We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals

70 hedge funds and large institutions have $58.8M invested in PMV Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

505% more call options, than puts

Call options by funds: $115K | Put options by funds: $19K

0% more capital inflows, than outflows

Capital inflows: $5.73M | Capital outflows: $5.72M

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.46% less ownership

Funds ownership: 75.75% → 75.28% (-0.46%)

5% less funds holding

Funds holding: 74 → 70 (-4)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

52% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 31

Holders
70
Holders Change
-4
Holders Change %
-5.41%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
6
Increased
15
Reduced
31
Closed
10
Calls
$115​K
Puts
$19​K
Net Calls
+$96​K
Net Calls Change
+$96​K

PMVP Hedge Fund Activity: Q4 2024 in Review

70 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2024, worth a combined $58.8M — up 1.2% from $58.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of PMVP and 6 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 15 added.

The largest buyer was BML Capital Management, adding an estimated $2.82M. The largest seller was Citadel Advisors, cutting an estimated $1.5M.

  • 70 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2024, down from 74 in Q3 2024.
  • Funds reported $58.8M of PMV Pharmaceuticals stock for Q4 2024, up 1.2% quarter-over-quarter.
  • 6 funds opened new PMV Pharmaceuticals positions in Q4 2024 and 10 closed out, a net change of -4 holders.
  • The largest PMV Pharmaceuticals buyer in Q4 2024 was BML Capital Management, an estimated $2.82M added.
  • The largest PMV Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $1.5M sold.

Based on aggregated 13F filings for Q4 2024.